– USA, NY – Acuamark Diagnostics, Inc., a biotechnology company that uses a unique approach to develop cost-effective blood-based screening tests for the early detection of cancer, today announced the addition of Brian C. Carr to its Board of Directors.
Mr. Carr is a seasoned industry executive with almost thirty years of experience in the diagnostic laboratory industry. He has also been involved in several early stage biotechnology companies focused on advancing precision medicine and on improving early disease detection.
Mr. Brian C. Carr states: “It’s an honor to be formally involved with a group of such leading scientists and executives, all of whom are uniformly driven to take on one of the greatest challenges and opportunities of our time in the fight against cancer. I’m eager to share in the commitment required to see Acuamark Diagnostics succeed.”
Amongst his various accomplishments, Mr. Carr started his laboratory career with Allied Clinical Laboratories before forming InformDX, which later merged with publicly-held AmeriPath. Mr. Carr subsequently served as President and Board Director of AmeriPath before co-founding and becoming Chairman and CEO of American Esoteric Laboratories, later acquired by Sonic Healthcare Limited, a publicly held Australian diagnostics company with operations worldwide. Mr. Carr then served as a co-founder and Chief Executive Officer of OralDNA Labs, a privately held salivary diagnostic company which was acquired by Quest Diagnostics in May 2009.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. comments: “Brian is a deeply engaged and thorough professional, and an experienced diagnostics industry leader. We are honored to welcome Brian into our midst and proud that he has decided to join our efforts.”
Mr. Michael Gargano, Chairman of the Board of Acuamark Diagnostics, further adds: “I would like to welcome Mr. Carr to the Board Of Directors of Acuamark Diagnostics. Brian brings a wealth of experience and will add tremendous industry depth to the Company’s Board as the organization grows.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics’ technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.